FAST BioMedical’s technology has the potential to favorably impact the treatment of people experiencing a broad range of diseases, including Heart Failure, Cardiorenal Syndrome, Sepsis and Acute Kidney Injury. These patients present with a variety of symptoms and experience high hospitalization and mortality rates. More effective, timely treatment can impact morbidity and mortality rates and has the potential to reduce overall costs.
Two key metrics with the potential to transform how clinicians determine therapy for these patients are intravascular volume status and kidney function. No clinically viable methods to simultaneously determine these metrics exist today. Measurements of weight, blood pressure, urine output and cardiac output correlate poorly with actual volume status. The standard of care directs physicians to make treatment decisions using subjective evaluation of edema and venous distension or listening for chest congestion. Physical assessments are imprecise and vary greatly from clinician to clinician, and may lead to less than optimal treatment.
90% of heart failure admissions are due to intravascular volume overload, yet there is no current way to measure volume.
- Costanzo, MR et al.1
1Costanzo, MR et al. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure. JACC 2007;40:675-683
